...
首页> 外文期刊>OncoTargets and therapy >A study on the effect of IL-6 gene polymorphism on the prognosis of non-small-cell lung cancer
【24h】

A study on the effect of IL-6 gene polymorphism on the prognosis of non-small-cell lung cancer

机译:IL-6基因多态性对非小细胞肺癌预后影响的研究

获取原文

摘要

Background: Lung cancer is one of the most commonly diagnosed clinical diseases. IL-6 is a multifunctional cytokine that is related to chemotactic factors and tumor biological regulation. -174G/C polymorphism in the promoter region of the IL-6 gene single-nucleotide polymorphism is the -174 position change from G to C. However, the relationship between the IL-6 gene polymorphism and prognosis of lung cancer is elusive. Therefore, the aim of this study was to evaluate the effect of -174G/C polymorphism on the prognosis of patients with non-small-cell lung cancer (NSCLC).Methods: DNA was extracted from the peripheral blood of 434 cases diagnosed with NSCLC by cytologic or histologic examination. Polymerase chain reaction–restriction fragment length polymorphism (NlaIII) was used to detect the genotype of -174G/C. Based on the functional activity of the IL-6 gene polymorphism, genotypes were divided into G vector (CG/GG) (high yield) and CC genotype (low yield). Prognosis of patients was analyzed and independent risk factors evaluated. A quantitative analysis of the degree of pain after diagnosis was performed to evaluate the correlations between gene polymorphisms and the degree of pain and use of analgesics.Results: Survival analysis showed that survival of the patients carrying the G allele (CG/GG) was significantly lower than that of patients with CC genotype (42.31 versus 62.79 months; P=0.032). The IL-6 gene promoter region revealed the presence of polymorphic variants, which may be associated with changes in the gene transcription process that affect the level of serum cytokines. IL-6 -174G/C gene polymorphism is associated with a significant morphine equivalent daily dose (IL-6 GG, 69.61; GC, 73.17; CC, 181.67; P=0.004). Homozygous IL-6 -174C/C genotype carriers required higher doses of opioids than GG or GC carriers.Conclusion: Polymorphism of -174G/C in IL-6 is closely related to cancer pain in NSCLC patients, the use of analgesics, and survival prognosis. It is necessary to further confirm the related results and determine the underlying pathogenic mechanisms.
机译:背景:肺癌是最常见的临床疾病之一。 IL-6是一种多功能的细胞因子,与趋化因子和肿瘤生物学调节有关。 IL-6基因单核苷酸多态性启动子区域中的-174G / C多态性是从G到C的-174位置变化。但是,IL-6基因多态性与肺癌预后之间的关系尚不清楚。因此,本研究旨在评估-174G / C基因多态性对非小细胞肺癌(NSCLC)患者预后的影响。方法:从434例确诊为NSCLC的患者外周血中提取DNA通过细胞学或组织学检查。用聚合酶链反应-限制性片段长度多态性(NlaIII)检测-174G / C的基因型。根据IL-6基因多态性的功能活性,将基因型分为G载体(CG / GG)(高产量)和CC基因型(低产量)。分析患者的预后并评估独立的危险因素。对诊断后的疼痛程度进行定量分析,以评估基因多态性与疼痛程度和使用止痛药之间的相关性。结果:生存分析表明,携带G等位基因(CG / GG)的患者的生存率显着低于CC基因型患者(42.31对62.79个月; P = 0.032)。 IL-6基因启动子区域显示多态性变体的存在,这可能与影响血清细胞因子水平的基因转录过程的变化有关。 IL-6 -174G / C基因多态性与显着的吗啡当量每日剂量相关(IL-6 GG,69.61; GC,73.17; CC,181.67; P = 0.004)。纯合子IL-6 -174C / C基因型携带者需要比GG或GC携带者更高剂量的阿片类药物。结论:IL-6中-174G / C的多态性与NSCLC患者的癌症疼痛,使用止痛药和生存密切相关。预后。有必要进一步确认相关结果并确定潜在的致病机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号